SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology
Leading community-based practice to utilize increased set of solid tumor applications
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024
Launch of new application enables global access to high-performing solid tumor profiling assay
Advancing precision oncology with MSK-ACCESS® powered with SOPHiA DDM™ – ELBS & SOPHiA GENETICS webinar (European Liquid Biopsy Society)
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, recently joined the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the...
SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research
BOSTON and ROLLE, Switzerland, November 6, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence...
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer
BOSTON, United States and ROLLE, Switzerland, November 5, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer (“CFO”) and Chief Operating...
SOPHiA GENETICS Reports Third Quarter 2024 Results
Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine,...
ESMO Asia 2024
We are thrilled to announce our participation in the ESMO Asia Congress 2024! Join the SOPHiA GENETICS team at booth #E406 and explore how we are driving groundbreaking innovations in cancer research and treatment. From our collaboration with Memorial Sloan...
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024
BOSTON and ROLLE, Switzerland, Oct. 22, 2024 -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud- native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before U.S....
How Predictive Analytics is Boosting Clinical Trials Efficiency?
Clinical trials are the backbone of modern medicine, responsible for bringing innovative, safe, and efficient treatments to market after rigorous testing and evaluation. However, the conventional process of conducting these trials has often been long, expensive, and fraught with inefficiencies¹. The advent of predictive analytics is reshaping the landscape of clinical trials, ushering in a new era of precision efficiency². This blog explores how predictive analytics is transforming clinical trials, from optimizing design and recruitment to predicting outcomes and reducing risks.
The Importance of Data Diversity to Enhance Clinical Trials Success
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹⁻³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and achieve global health equity.
Matched tumor-normal sequencing: The preferred method for identifying somatic mutations driving tumorigenesis
Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty.
ECP Posters spotlight
We recently presented two posters at the European Congress of Pathology 2024, in Florence, Italy, in collaboration with Janssen Pharmaceutical, a Johnson & Johnson company. The posters provided real-world data insights on the genomic landscape of specific...
Case Study: Implementing comprehensive clinical exome analysis to support diverse applications at Henry Ford Health
See how Henry Ford Health enhanced their genetic testing by adopting exome sequencing for hereditary cancer, cystic fibrosis, and pharmacogenetics applications.
From Data to Decisions, Faster than Ever: Pioneering the future of precision medicine with the New Generation SOPHiA DDM™ Platform
In response to the emerging needs in global healthcare, SOPHiA GENETICS has just revealed the New Generation SOPHiA DDM™ Platform, aiming to stay at the forefront of precision medicine and address today the healthcare needs of tomorrow.
Guidelines Spotlight: ESMO urge NGS testing for additional advanced cancers
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers.
